Prof. PeptideProf. Peptide
Reference

Peptide half-life chart

Peptide half-lives at a glance: semaglutide about 7 days, tirzepatide about 5 days, retatrutide about 6 days, ipamorelin about 2 hours and PT-141 about 2.7 hours. Each figure below cites its label or study, and a compound with no published figure says so rather than showing a number.

Sourced the figure comes from an FDA label or a published study, linked in the row. Partly sourced a blend, or a compound with two forms, where only some parts have a published figure. Not published in the figure column: no label or study gives a figure.

Half-life by compound

Metabolic & GLP-1

CompoundPublished figureStatusSource
5-Amino-1MQ

Not published

—

—

Adipotide

Not published

—

—

AOD-9604

Not published

—

—

AOD-9604 + MOTS-c

Not published

—

—

Cagrilintide

about 7 to 8 days (174 and 186 hours) alone, in two studies; 6.6 to 8.1 days (159 to 195 hours) given with semaglutide

Sourced

Nielsen et al., Clin Pharmacokinet 2026;65(7):1087-99 (NCT04209049, NCT05564104).

CagriSema

Cagrilintide: 6.6 to 8.1 days (159 to 195 hours)

Semaglutide: 6 to 6.9 days (145 to 165 hours)

Sourced

Enebo et al., Lancet 2021 — cagrilintide 159–195 h when co-administered with semaglutide 2.4 mg.

Enebo et al., Lancet 2021 — semaglutide 2.4 mg 145–165 h when co-administered with cagrilintide.

HGH Fragment 176-191

Not published

—

—

Mazdutide

Not published

—

—

Metabolic Blend (NAD+ / MOTS-c / 5-Amino-1MQ)

Not published

—

—

MOTS-c

Not published

—

—

Retatrutide

about 6 days

Sourced

Urva et al., Lancet 2022 — Phase 1b study in type 2 diabetes ("its half-life was approximately 6 days"); retatrutide is investigational.

Semaglutide

about 7 days

Sourced

Wegovy and Ozempic (semaglutide) FDA prescribing information.

Semaglutide + BPC-157

Semaglutide: about 7 days

BPC-157: Not published

Partly sourced

OZEMPIC (semaglutide) prescribing information — "the long half-life of OZEMPIC of approximately 1 week".

—

Survodutide

Not published

—

—

Tirzepatide

about 5 days

Sourced

Mounjaro (tirzepatide) FDA prescribing information.

Tirzepatide + BPC-157

Tirzepatide: about 5 days

BPC-157: Not published

Partly sourced

MOUNJARO (tirzepatide) prescribing information — "the half-life of tirzepatide of approximately 5 days".

—

Recovery & Tissue Repair

CompoundPublished figureStatusSource
BPC-157

Not published

—

—

Cibinetide (ARA-290)

Not published

—

—

PDA (Pentadeca Arginate)

Not published

—

—

TB-500

Not published

—

—

Wolverine Stack

BPC-157: Not published

TB-500: Not published

—

—

—

Performance & Energy

CompoundPublished figureStatusSource
IGF-1 DES

Not published

—

—

IGF-1 LR3

Not published

—

—

MGF

Not published

—

—

Follistatin

Not published

—

—

Growth Hormone

CompoundPublished figureStatusSource
CJC-1295

no-DAC / Mod GRF 1-29: Not published

with DAC: 5.8 to 8.1 days

Partly sourced

—

Teichman et al., J Clin Endocrinol Metab 2006 — CJC-1295 with DAC.

CJC-1295 (No DAC) + Ipamorelin (GH Stack)

CJC-1295 (no-DAC): Not published

Ipamorelin: about 2 hours

Partly sourced

—

Gobburu et al., Pharm Res 1999;16(9):1412–6 — terminal half-life 2 hours.

GHRP-2

Not published

—

—

GHRP-6

Not published

—

—

Hexarelin

Not published

—

—

Ipamorelin

about 2 hours

Sourced

Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412–6 — terminal half-life 2 hours.

MK-677

Not published

—

—

MK-677 + Ipamorelin

MK-677: Not published

Ipamorelin: about 2 hours

Partly sourced

—

Gobburu et al., Pharm Res 1999;16(9):1412–6 — terminal half-life 2 hours.

Sermorelin

Not published

—

—

Sermorelin + Ipamorelin

Sermorelin: Not published

Ipamorelin: about 2 hours

Partly sourced

—

Gobburu et al., Pharm Res 1999;16(9):1412–6 — terminal half-life 2 hours.

Tesamorelin

Egrifta WR: about 11 minutes

Egrifta SV: about 8 minutes

Sourced

EGRIFTA WR prescribing information, Clinical Pharmacology — Elimination.

EGRIFTA SV prescribing information, Clinical Pharmacology — Elimination.

Tesamorelin + Ipamorelin

Tesamorelin: about 11 minutes

Ipamorelin: about 2 hours

Sourced

EGRIFTA WR prescribing information, Clinical Pharmacology — Elimination.

Gobburu et al., Pharm Res 1999;16(9):1412–6 — terminal half-life 2 hours.

Cognitive & Nootropic

CompoundPublished figureStatusSource
Adamax

Not published

—

—

Dihexa

Not published

—

—

Selank

Not published

—

—

Semax

Not published

—

—

PE-22-28

Not published

—

—

Semax + Selank

Not published

—

—

Skin Health & Anti-Aging

CompoundPublished figureStatusSource
AHK-Cu

Not published

—

—

GHK-Cu

Not published

—

—

GLOW

Not published

—

—

KLOW

Not published

—

—

Melanotan I (Afamelanotide)

about 15 hours, from the controlled-release implant

Sourced

SCENESSE (afamelanotide) implant prescribing information.

Melanotan II

Not published

—

—

SNAP-8

Not published

—

—

Gut Health & Immunity

Sleep & Recovery

CompoundPublished figureStatusSource
DSIP

Not published

—

—

Longevity

CompoundPublished figureStatusSource
Epitalon

Not published

—

—

Glutathione (GSH)

Not published

—

—

NAD+

Not published

—

—

FOXO4-DRI

Not published

—

—

SS-31 (Elamipretide)

Not published

—

—

Bioregulators

CompoundPublished figureStatusSource
Pinealon

Not published

—

—

Thymogen

Not published

—

—

Cortagen

Not published

—

—

Cardiogen

Not published

—

—

Cartalax

Not published

—

—

Crystagen

Not published

—

—

Thymalin

Not published

—

—

Sexual Health

Peptide half-life FAQ

What does peptide half-life mean?
A peptide's half-life is the time it takes for half of a dose to be cleared from the blood. It is a measured pharmacokinetic figure, not how long an effect lasts: semaglutide's is about 7 days on its label, while many research peptides clear in minutes or have no published figure at all.
What is the half-life of tesamorelin?
Tesamorelin's half-life is about 11 minutes for Egrifta WR and about 8 minutes for Egrifta SV, the two approved formulations, per their prescribing information. Both figures are measured after a single subcutaneous dose in healthy volunteers, and research-grade tesamorelin has no label of its own.
What is the half-life of BPC-157?
No published human pharmacokinetic study establishes BPC-157's half-life. A figure of under 30 minutes in plasma is commonly repeated, and the BPC-157 profile reports it as that; with no study behind it, the chart lists BPC-157, and its blends' BPC-157 component, as not published.
What is the half-life of MOTS-c?
No half-life is published for MOTS-c: no pharmacokinetic study of it in people has been published, and it has no label. Most research peptides, including KPV, AOD-9604 and DSIP, have no published half-life either, so the chart lists them as not published rather than giving a number.
What is the half-life of KPV?
KPV has no published half-life in people: no pharmacokinetic study has given it to people, and it has no label. Its blends with BPC-157 and in KLOW carry no published figure either, so the chart lists all three as not published.
What is the half-life of SS-31?
SS-31's label, Forzinity, gives no half-life. It reports that peak blood levels came 0.5 to 1 hour after a subcutaneous dose, which is an absorption figure, not a half-life, so the chart lists SS-31 as not published.
Does half-life tell how long a peptide's effects last?
No. Half-life describes clearance from the blood. How long an effect lasts depends on receptor binding and downstream signaling, which can outlast the compound itself: growth-hormone-releasing peptides clear in minutes but drive a growth-hormone pulse lasting hours.
Is there a peptide half-life calculator?
Yes. The half-life visualizer plots how much of a dose remains over time for any compound with a sourced half-life, and the semaglutide, tirzepatide and GLP-1 half-life calculators model weekly dosing from each label's figure. Each uses the same sourced figures as this chart.

Sources: each figure links to the FDA label or published study it comes from, as cited on the compound’s own profile; Prof. Peptide read them between September and November 2026.

Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.

Checked and updated